Supporter News

Day 1: Friday, 27 September 2024 – A Strong Start to CLL Horizons 2024

27th September 2024 Source: CLL (visit site)
The first day of CLL Horizons 2024 began at noon with a warm Opening Lunch on the Evolution Terrace, where participants were welcomed by the event team. Over lunch, attendees were introduced to the structure of the conference and received guidance on navigating the sessions ahead. Don’t miss the highlights! View our 2-minute video recap below. Workshops: Building…

Registration for attending CLL Horizons 2024 in-person is now closed. Final call for virtual registration!

17th September 2024 Source: https://www.clladvocates.net (visit site)
The CLL Advocates Network (CLLAN) Steering Committee is thrilled to announce the return of our highly anticipated in-person event after the pandemic hiatus. Our 5th conference promises a blend of in-person and virtual experiences scheduled for 27th – 29th September in Barcelona, Spain.  Final call for virtual registration! – CLICK HERE TO REGISTER Draft Agenda: You can view draft…

Spotlight on ALAN members

27th August 2024 Source: https://acuteleuk.org (visit site)
In 2024, with ALAN support, some of our members have been able to start and/or complete projects which benefit acute leukemia patients and their families. We are very grateful that our support could contribute to make these projects happen. Aim: provide accurate and comprehensive information to support shared decision-making among those impacted by acute leukemia,…

EHA 2024

From 12th to 16th June, ALAN attended the European Hematology Association (EHA) 2024 congress, held in Madrid, Spain. Below is a summary of the activities in which ALAN took part, in addition to meeting with our members, sponsors and with the medical community. We are also reporting on the key sessions and latest advances. Check here…

Highlights from EHA – Infographic gallery

Download your copy and discover the core insights from EHA Congress, condensed into a dynamic infographic. Acute promyelocytic LEUKEMIA (APL) FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK APL APL APOLLO Trial Acute lymphoblastic leukemia (ALL)…